Skip to main content
Equibles
TTRX logo

TTRX · Turn Therapeutics Inc. · Investor Relations

Track TTRX — free

Use TTRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TTRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.48 +0.54 (+6.04%) At close · Nov 6
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Our capital resources may not be sufficient to fund operations through at least the next 12 months from the date that the accompanying unaudited condensed consolidated interim financial statements as of June 30, 2026 are issued based on our expected cash needs, which raises substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$282.39M
Shares
29.79M
Volume · Nov 6 98.14K Avg daily vol (3M) 110.55K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-09-10 Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
2026-09-09 Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
2026-08-12 Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
2026-07-07 Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
2026-06-01 Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
2026-05-27 Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
2026-05-19 Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
2026-05-18 Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
2026-05-11 Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-03-31 Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
2026-03-24 Turn Therapeutics Secures Up to $25 Million in Financing from Avenue Capital Group
2026-02-17 Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
2026-02-09 Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
2026-01-12 Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
2026-01-07 Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
2025-11-13 Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
2025-11-12 Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.
2025-11-12 Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine
2025-11-04 Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications

Past events

Date Event Type
2026-09-23 Stifel 2026 Virtual Immunology and Inflammation Forum Webcast
2026-07-07 GX-03 Phase 2 Update: A Detailed Review of Key Stage 1 Findings and the Data-Driven Stage 2 Design Webcast
2026-06-04 Jefferies Global Healthcare Conference 2026 Conference
2026-03-02 46th Annual TD Cowen Healthcare Conference in Boston, MA Conference
2026-02-25 36th Annual Oppenheimer Healthcare Life Sciences Conference (Virtual) Conference

Source: https://ir.turntherapeutics.com/

Key facts CIK 2023016 CUSIP 90021W105 13F (30d) 16 filings 16 filers Visit website Investor relations